Combinations of anti-staphylococcus aureus antibodies
AssigneeMedImmune, LLC
InventorsChristine TKACZYK, Bret SELLMAN, Qun DU, Melissa DAMSCHRODER, Taylor COHEN
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.
Claims36
A method of preventing a Staphylococcus aureus (S. aureus) infection in a subject comprising administering to the subject (a) an antibody or antigen-binding fragment thereof that binds to S. aureus alpha toxin (AT), (b) an antibody or antigen-binding fragment thereof that binds to S. aureus clumping factor A (ClfA), and (c) an antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin.
A method of treating or preventing a Staphylococcus aureus (S. aureus) infection in a subject comprising administering to the subject an antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin and (a) an antibody or antigen-binding fragment thereof that binds to S. aureus alpha toxin (AT) or (b) an antibody or antigen-binding fragment thereof that binds to S. aureus clumping factor A (ClfA).
A composition comprising (a) an antibody or antigen-binding fragment thereof that binds to S. aureus AT, (b) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA, and (c) an antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin.
A composition comprising an antibody or antigen-binding fragment thereof that binds to at least one S. aureus leukotoxin and (a) an antibody or antigen-binding fragment thereof that binds to S. aureus AT or (b) an antibody or antigen-binding fragment thereof that binds to S. aureus ClfA.
5-12. (canceled)
16-19. (canceled)
21-34. (canceled)
39-40. (canceled)
43-45. (canceled)
47-65. (canceled)
67-69. (canceled)
73-76. (canceled)
78-93. (canceled)
95-109. (canceled)
111-118. (canceled)
A method of treating or preventing a S. aureus infection in a subject with diabetes comprising administering to the subject an antibody or antigen-binding fragment thereof that binds to S. aureus AT.
121-160. (canceled)
Dependencies are inferred from the claim text.